Researchers from Kexing Biopharm Co. Ltd. have published details on the development and preclinical characterization of GB18-06, a novel nanobody, also known as variable domain of heavy-chain antibody ...

In their report, titled “Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy,” the researchers commented, “Altogether ...

Utilizing the phage antibody library approach, Sino Biological has independently built a platform for the production of nanobodies and has produced numerous successful nanobody candidates.

Due to the ease of nanobody engineering, they can be employed in three nanobody-based therapeutic platforms: platform A, receptor antagonists to interfere with or block the activation of a certain ...

More information: Jun Yu et al, Structural basis of μ-opioid receptor targeting by a nanobody antagonist, Nature ...